Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Dr. Reddy’s Laboratories Ltd has announced its first quarter results for the financial year 2024-25 on Saturday, July 27.
Also Read: Bajaj, India’s top rickshaw maker sees bright future in CNG motorbikes
The pharmaceuticals giant’s consolidated revenue grew to ₹7,672.7 crore, which is a rise of 13.86% or ₹934.3 crore, compared to ₹6,738.4 crore in the first quarter of the financial year 2023-24.
Also Read: Ola Electric’s ₹5,500 crore IPO to launch next Friday on August 2
The net profit however, fell to 1,392 crore. This was a drop of 0.74% or ₹10.5 crore, compared to the same quarter of the previous year’s net profit of ₹1,402.5 crore.
Global generic drugs made up for most of the revenue, contributing ₹6,885.8 crore to it. This was an increase of 14.60% or ₹877.5 crore, compared to ₹6,008.3 crore in Q1 2023-24.
Pharmaceutical services and active ingredients contributed ₹1,030.9 crore to the revenue. This was an increase of 11.83% or ₹109.1 crore, compared to ₹921.8 crore in the same quarter of the previous year.
When it comes to net profit, global generics contributed ₹4,451.8 crore. This was an increase of 15.97% or ₹613.1 crore compared to the same quarter of the previous year’s ₹3,838.7 crore.
Pharmaceutical services and active ingredients contributed ₹176.8 crore to the net profit. This was an increase of 75.22% or ₹75.9 crore compared to ₹100.9 crore in the first quarter of the financial year 2023-24.
Global Generics
The profit before tax was ₹1,882.1 crore, an increase of 19.39% or ₹35.8 crore from ₹1,846.3 crore in Q1 2023-24.
Dr. Reddy’s Laboratories incurred total operating expenses of ₹2,841.9 crore. This was an increase of 29.66% or ₹650.2 crore, compared to ₹2,191.7 crore in the same quarter of the previous year.
Also Read: Abbott fined $500m in US for allegedly hiding infant formula fatal disease risk
The company incurred research and development (R&D) expenses of ₹619.3 crore in Q1 2024-25. This was an increase of 24.25% or ₹120.9 crore from ₹498.4 crore in the first quarter of the previous year.
Selling, general and administrative expenses added up to ₹2,269.1 crore, an increase of 28.18% or ₹498.9 crore, compared to ₹1,770.2 crore in Q1 2023-24.
Dr. Reddy’s Laboratories’ shares closed at ₹6,892.15 on the Bombay Stock Exchange after Friday’s trading session, yesterday on July 26. This was an increase of 0.55% or 37.95 points compared to the previous close.